Cartesian Therapeutics

RNAC

Market cap $176M

Cartesian Therapeutics (RNAC) is maintained at a "Buy" rating, driven by progress in its Descartes-08 mRNA CAR-T pipeline for autoimmune disorders. RNAC's phase 3 AURORA study targets AChR Ab+ myasthenia gravis, with positive long-term phase 2b data supporting ongoing late-stage development. Positive signals in systemic lupus erythematosus prompted RNAC to prioritize myositis, an underserved market with high unmet need, for possible pivotal trials.

FREDERICK, Md., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, today announced the granting of inducement awards to two new employees. On October 27, 2025, the Company issued to one employee an option to purchase an aggregate of 50,000 shares of the Company's common stock with an exercise price of $8.85, the closing trading price of the Company's common stock on the Nasdaq Global Market on the date of grant. On October 29, 2025, the Company issued to another employee an option to purchase an aggregate of 2,650 shares of the Company's common stock with an exercise price of $8.20, the closing trading price of the Company's common stock on the Nasdaq Global Market on the date of grant. The options were granted pursuant to the Company's Amended and Restated 2018 Employment Inducement Incentive Award Plan and were approved by the Company's board of directors. The first employee's option vests as to 25% on October 27, 2026, and then in three equal annual installments thereafter such that the option will be fully vested on October 27, 2029. The second employee's option vests as to 25% on October 29, 2026, and then in three equal annual installments thereafter such that the option will be fully vested on October 29, 2029. The options have a ten-year term. The options were granted under Rule 5635(c)(4) of the Nasdaq Listing Rules as an inducement material to the employees' entry into employment with the Company.

Cartesian Therapeutics, Inc. (RNAC) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

FREDERICK, Md., Oct. 03, 2025 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, today announced the granting of an inducement award to one new employee. On October 2, 2025, the Company issued to this employee an option to purchase an aggregate of 9,700 shares of the Company's common stock with an exercise price of $10.34, the closing trading price of the Company's common stock on the Nasdaq Global Market on the date of grant. The option was granted pursuant to the Company's Amended and Restated 2018 Employment Inducement Incentive Award Plan and was approved by the Company's board of directors. The option vests as to 25% on October 2, 2026, and then in three equal annual installments thereafter such that the option will be fully vested on October 2, 2029. The option has a ten-year term. The option was granted under Rule 5635(c)(4) of the Nasdaq Listing Rules as an inducement material to the employee's entry into employment with the Company.

Cartesian Therapeutics, Inc. (NASDAQ:RNAC ) Morgan Stanley 23rd Annual Global Healthcare Conference September 9, 2025 4:05 PM EDT Company Participants Carsten Brunn - President, CEO & Director Milos Miljkovic - Chief Medical Officer Conference Call Participants Ross Cohen - Morgan Stanley Presentation Ross Cohen So really quickly on disclosures. So for important disclosures, please see the Morgan Stanley research disclosure website.

FREDERICK, Md., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, today announced that its management expects to participate in the following investor conferences in September:

Cartesian (RNAC) Q2 Revenue Drops 99%

Cartesian Therapeutics, Inc. (RNAC) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.

FREDERICK, Md., June 03, 2025 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, today announced the granting of inducement awards to three new employees. On June 2, 2025, the Company issued to these employees options to purchase an aggregate of 26,350 shares of the Company's common stock with an exercise price of $9.98, the closing trading price of the Company's common stock on the Nasdaq Global Market on the date of grant. The options were granted pursuant to the Company's Amended and Restated 2018 Employment Inducement Incentive Award Plan and were approved by the Company's board of directors. The options vest as to 25% on June 2, 2026, and then in three equal annual installments thereafter such that the options will be fully vested on June 2, 2029. The options have a ten-year term. The options were granted under Rule 5635(c)(4) of the Nasdaq Listing Rules as an inducement material to the employees' entry into employment with the Company.

FREDERICK, Md., May 30, 2025 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (“Cartesian” or the “Company”), a clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, today announced that the first participant has been enrolled in its Phase 3 AURORA trial of Descartes-08 in patients with myasthenia gravis (MG).